With new approach to Alzheimer's, Peninsula company seals $225M deal with drug giant AbbVie
October 24, 2017 at 07:00 AM EDT
The same way cancer-fighting companies have tapped the immune system to uncloak and attack tumor cells, this South San Francisco startup is targeting its drug at multiplying and directing a key cell connected to the immune system in the brain to attack Alzheimer's-related dementia and other brain conditions.
